[1] |
MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu.
Correlation between 25(OH)D and metabolically related fatty liver in T2DM population
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
|
[2] |
WANG Donghui, JIANG Suwen, HU Airong, ZHU Bo, HE Zheyun, ZHANG Lukan, WANG Jialan, FAN Ying, LIN Ken .
Mulberry exerts antioxidant stress effect in rats with nonalcoholic fatty liver disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 609-616.
|
[3] |
LI Junmin, NIU Hengli, XIE Mingquan, SU Jinlong.
Effects of hawthorn flavonoids on atherosclerotic and hyperlipidemia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 276-282.
|
[4] |
MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling.
Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
|
[5] |
WANG Ruijie, WANG Liang, XU Dan, ZHOU Miaomiao, LI Jiming.
Effects of PCSK9 inhibitors on blood lipids and inflammatory factors in patients with coronary heart disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 409-417.
|
[6] |
ZHANG Liang, LIAO Yongqun, XIA Qinchuan, ZHOU Shitong, LI Xiaoli.
Ferroptosis regulatory signaling pathway and its research progress in related diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 227-234.
|
[7] |
SONG Ruzheng, PENG Ying, WANG Guangji, SUN Jianguo.
Commonly used quantitative proteomics research techniques and their application in the study of pathogenesis of liver-derived diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 570-578.
|
[8] |
WU Jiayuan, ZHENG Li, MO Juanfen, GUO Li, CAO Chenxi, BAO Yi.
Regulation of N-acetylcysteine on peripheral circulatory and hepatic myeloid-derived suppressor cells in non-alcoholic fatty liver disease mice
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 989-996.
|
[9] |
CHEN Xi, LING Jiawei, DING Jiaxin, JIANG Zhenzhou, ZHANG Luyong.
Advances in pathogenesis of nonalcoholic fatty liver disease caused by tamoxifen
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 715-720.
|
[10] |
ZHOU Hongping, YANG Xingxin, ZHUANG Rangxiao, SHAO Yidan, XI Jianjun, LIAO Li, REN Bailu, WANG Pingping, YU Shuying, SHI Tingting.
Effects of activated carbon N-acetylcysteine sustained-release microcapsule on miRNA of non-alcoholic fatty liver disease in young rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 263-270.
|
[11] |
XIE Zhen, KANG Hua, HE Licheng, KUANG Rong.
Effects and mechanism of deep-sea fish oil on blood lipid in hyperlipidemia rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 870-874.
|
[12] |
YANG Yilin, ZHENG Linying, GU Weiming, PAN Jingqiang, WU Xin,LI Yaojun.
Effect of total glucosides of paeony regulate HMGB1, RAGE pathway on nonalcoholic fatty liver disease in rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 611-616.
|
[13] |
LU Yong-juan, CHEN Zhi-yun, YAN Mao-xiang, HE Bei-hui, ZHU Dan.
Effect of atorvastatin on adipokines in rats with nonalcoholic fatty liver disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 520-524.
|
[14] |
JI Xue-lei, GE Yi-dong, AN Min-min, LIU Lei, DING Jun, XIE Yu-xin, LI Chun-yun.
Correlation analysis between nonalcoholic fatty liver disease and metabolic syndrome
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(6): 666-670.
|
[15] |
LI Rong-hui, HUANG Mei-ling, TAN Hong-yi, PEI Qi, XIANG Yu-xia, YANG Guo-ping.
Advances of the influence of nonalcoholic fatty liver disease on the pharmacokinetics
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(9): 1065-1075.
|